Find the Right Market Report

Search thousands of industry reports, market insights, and research studies in one place.

Not sure where to start? Try one of these:
Explore healthcare market intelligence and industry insights
Towards Healthcare

Patient-Derived Xenografts/PDX Models Key Players and their Developments

Date : 22 May 2026

Top Companies in the Patient-Derived Xenografts/PDX Models Market & Their Offerings

Patient Derived XenograftsPDX Models Market Companies are Charles River Laboratories, The Jackson Laboratory, Crown Bioscience, Altogen Labs, Envigo (Inotiv), WuXi AppTec, Oncodesign Services

Companies Headquarters Offerings
Charles River Laboratories Massachusetts, USA Large PDX tumor libraries, in vivo oncology testing, translational cancer research models, and drug efficacy evaluation services. 
The Jackson Laboratory  Bar Harbor, Maine, USA Provides mouse models, PDX systems, tumor biology research platforms, and precision oncology testing tools.
Crown Bioscience California, USA Delivers extensive PDX model platforms, immuno-oncology testing, biomarker research, and preclinical oncology services.
Altogen Labs Texas, USA Focuses on PDX model development, xenograft studies, and in vivo cancer drug testing for preclinical research.
Envigo (Inotiv) Indiana, USA Provides laboratory animal models, PDX and xenograft services, and toxicology and safety testing support.
WuXi AppTec Shanghai, China Offers integrated drug development services, including PDX models, oncology screening, and preclinical research support.
Oncodesign Services Dijon, France Specializes in PDX oncology models, translational pharmacology, and targeted cancer drug evaluation services

What are the Recent Developments in the Patient-Derived Xenografts/PDX Models Market? 

  • In May 2025, the NIH partnered with the FDA to reduce reliance on animal testing in funded research, encouraging the shift toward more human-relevant models. This move is expected to accelerate the adoption of advanced platforms like PDX alternatives in preclinical studies.
  • In April 2025, the FDA announced a 3–5 year plan to gradually remove animal testing requirements for monoclonal antibody development. This shift increases the importance of PDX models and other advanced preclinical data as key supporting evidence in IND submissions.

Supply Chain Analysis

R&D:

  • Patient-derived xenograft models support oncology research through tumor implantation, biomarker discovery, drug screening, genomic profiling, and translational studies. Advanced mouse models, AI analytics, and biobanking technologies improve reproducibility, precision, and preclinical validation efficiency.
  • Companies: Champions Oncology, The Jackson Laboratory, Crown Bioscience, Charles River Laboratories, Hera BioLabs, Inotiv, Taconic Biosciences

Clinical Trials & Regulatory Approvals:

  • PDX models accelerate clinical trial design by predicting therapeutic responses, validating biomarkers, and supporting precision medicine strategies. Regulatory agencies increasingly recognize translational evidence generated through PDX studies for oncology drug development submissions globally.
  • Companies: Labcorp Drug Development, Eurofins Scientific, Pharmaron, WuXi AppTec, Covance, Crown Bioscience, Charles River Laboratories

Patient Support & Services:

  • Patient support services in PDX workflows include tumor sample collection, biobanking, genomic analysis, personalized therapy recommendations, logistics coordination, and physician collaboration, ensuring efficient integration of precision oncology solutions into clinical practice.
  • Companies: Xentech, Champions Oncology, Tempus, Caris Life Sciences, Precision for Medicine, LabConnect, ICON plc

Market Growth

The global patient-derived xenografts/PDX models market size was estimated at USD 612.4 million in 2025 and is predicted to increase from USD 696.91 million in 2026 to approximately USD 2230.79 million by 2035, expanding at a CAGR of 13.8% from 2026 to 2035.

Patient Derived XenograftsPDX Models Market Size is USD 696.91 Million in 2026.

Ready to make better
healthcare business decisions?

Speak with a healthcare analyst about your research, consulting, or platform needs.

Talk to an Analyst Contact Sales